Evidence map›Paper›PMID 42151204›Full record

ArticleScientific reports2026

Real-time bioluminescence imaging of mycobacteria with Akaluc: a novel method for monitoring drug efficacy.

Md Shafiul Islam, Atsuki Takeishi, Yoshitaka Tateishi, Akihito Nishiyama, Yuriko Ozeki, Yutaka Yoshida, Amina Kaboso Shaban, Takeshi Annoura, Satoshi Iwano, Takasuke Fukuhara and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Md Shafiul IslamDepartment of Bacteriology, Graduate School of Medical and Dental Sciences, Niigata University, 757 Ichibancho, Asahimachi-dori, Chuo-Ku, Niigata, 951-8510, Japan. shafiul.med@gmail.com.
Atsuki TakeishiDepartment of Bacteriology, Graduate School of Medical and Dental Sciences, Niigata University, 757 Ichibancho, Asahimachi-dori, Chuo-Ku, Niigata, 951-8510, Japan.
Yoshitaka TateishiDepartment of Microbiology, Fukushima Medical University, 1Hikariga-oka, , Fukushima City, 960-1295, Japan.
Akihito NishiyamaDepartment of Bacteriology, Graduate School of Medical and Dental Sciences, Niigata University, 757 Ichibancho, Asahimachi-dori, Chuo-Ku, Niigata, 951-8510, Japan.
Yuriko OzekiDepartment of Bacteriology, Graduate School of Medical and Dental Sciences, Niigata University, 757 Ichibancho, Asahimachi-dori, Chuo-Ku, Niigata, 951-8510, Japan.
Yutaka YoshidaDepartment of Bacteriology, Graduate School of Medical and Dental Sciences, Niigata University, 757 Ichibancho, Asahimachi-dori, Chuo-Ku, Niigata, 951-8510, Japan.
Amina Kaboso ShabanDepartment of Bacteriology, Graduate School of Medical and Dental Sciences, Niigata University, 757 Ichibancho, Asahimachi-dori, Chuo-Ku, Niigata, 951-8510, Japan.
Takeshi AnnouraDepartment of Parasitology, National Institute of Infectious Diseases (NIID), Japan Institute for Health Security (JIHS), Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.
Satoshi IwanoInstitute for Tenure Track Promotion, University of Miyazaki, Miyazaki, Miyazaki, 889-2192, Japan.
Takasuke FukuharaDepartment of Virology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Sohkichi MatsumotoDepartment of Bacteriology, Graduate School of Medical and Dental Sciences, Niigata University, 757 Ichibancho, Asahimachi-dori, Chuo-Ku, Niigata, 951-8510, Japan. sohkichi@med.niigata-u.ac.jp.

Funding

AMED-CREST 22gm1610009Japan Agency for Medical Research and Development JP223fa627005Japan Society for the Promotion of Science 21KK0136Japan Society for the Promotion of Science 23K06543Japan Society for the Promotion of Science 24K10216Japan Society for the Promotion of Science 25K18794
6 · The paper itself

Abstract

Tuberculosis (TB) still threatens human life despite the availability of childhood vaccination and modern treatment regimens due to the emergence of tuberculosis with extended resistance profiles. The mouse active TB model remains the gold standard for evaluating anti-TB drugs and vaccines. However, in vivo experiments raise ethical concerns and are time-consuming. We established an Akaluc-based bioluminescence platform to enable rapid drug screening in culture media and THP‑1 cells. Codon-optimized Akaluc expression in mycobacteria was accomplished by assortment of vectors and promoters. Bioluminescence kinetics were evaluated in culture media and THP‑1 cells with or without drug treatment, and optimized by adjusting time points and substrate concentrations. TokeOni at a concentration of 10 nM/100 µL produced the highest bioluminescence compared to other tested concentrations and substrates. Among the tested promoter-plasmid constructs, the Ag85B promoter in pMV261 generated the strongest bioluminescence in Mycobacterium smegmatis and Mycobacterium bovis. Bioluminescence fluctuated with bacterial growth, peaking during the log phase and gradually declining during the stationary phase. A positive correlation was observed between bioluminescence and CFU reduction in vitro upon treatment with sensitive drugs.

Indexed as

Antitubercular AgentsLuminescent MeasurementsMycobacterium bovisMycobacterium smegmatisAcyltransferasesAnimalsAntigens, BacterialBacterial ProteinsHumansMycobacterium tuberculosisPromoter Regions, GeneticTHP-1 CellsAcyltransferasesAntigens, BacterialAntitubercular AgentsBacterial ProteinsAkalucAntigen 85B (Ag85B)Bioluminescence imagingDrug efficacyTokeOniTuberculosis

Identifiers

PMID42151204
PMCPMC13183891

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.